The Rutgers Cancer Institute of New Jersey announced it has begun a clinical trial that will examine whether an anti-malaria drug doctors are administering as an off-label use to treat the coronavirus is more effective when taken with an antibiotic. Clinical trials take year to complete. But Rutgers, a nationally recognized comprehensive cancer center, has the in-house expertise to move faster, said Rutgers Cancer Institute Director Steven K. Libutti, who is overseeing the trial. To read the full article.
Recent Posts
- Family Sparks NJIT Scholar’s Research into Biomedical Engineering.
- Extreme Monsoon Changes Threaten the Bay of Bengal’s Role as a Critical Food Source.
- New NJACTS Publication
- Join NJ ACTS Biostatistics, Epidemiology, Research Design (BERD) Workshop Series on June 19th
- NJIT Study Probes Genetic ‘Smoking Gun,’ Health Risks of Vaping Among Gen Z.
Categories
- Community (2,271)
- Covid (986)
- CTO Events (6)
- News (2,893)
- Pilots (21)